» Articles » PMID: 2834001

An Endogenous Substance with Clonidine-like Properties: Selective Binding to Imidazole Sites in the Ventrolateral Medulla

Overview
Journal Brain Res
Specialty Neurology
Date 1988 Feb 16
PMID 2834001
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

We sought to characterize the interactions of an endogenous clonidine-displacing substance (CDS) with the specific receptor sites to which clonidine and its analogs bind: (a) the non-adrenergic imidazole binding site, which is present in the ventrolateral medulla (VLM) but not the frontal cortex, (b) high-affinity and (c) low-affinity states of the alpha 2-adrenergic receptor, and (d) the alpha 1-adrenergic receptor. CDS, like clonidine, potently and completely inhibited specific p-[3H]aminoclonidine binding to membranes from the VLM or from the frontal cortex. Both CDS and clonidine bound with highest affinity to imidazole binding sites in the VLM, both were 3-fold selective for high-affinity over low-affinity alpha 2-adrenergic receptors, and both exhibited lowest affinity for alpha 1-adrenergic receptors. Unlike clonidine, CDS exhibited 30-fold selectivity for imidazole over alpha 2-adrenergic receptors but showed only a weak preference for alpha 2- over alpha 1-adrenergic receptors, indicating that CDS and clonidine are not identical. We conclude that CDS is an endogenous clonidine-like substance which may be the natural ligand for imidazole binding sites in the VLM. The receptor-binding properties of CDS are consistent with the view that it is a unique and as yet unrecognized compound.

Citing Articles

Adrenergic nervous system in heart failure: pathophysiology and therapy.

Lymperopoulos A, Rengo G, Koch W Circ Res. 2013; 113(6):739-53.

PMID: 23989716 PMC: 3843360. DOI: 10.1161/CIRCRESAHA.113.300308.


Central mechanisms of abnormal sympathoexcitation in chronic heart failure.

Kishi T, Hirooka Y Cardiol Res Pract. 2012; 2012:847172.

PMID: 22919539 PMC: 3420224. DOI: 10.1155/2012/847172.


Neuroprotection by alpha 2-adrenergic agonists in cerebral ischemia.

Zhang Y, Kimelberg H Curr Neuropharmacol. 2008; 3(4):317-23.

PMID: 18369397 PMC: 2268994. DOI: 10.2174/157015905774322534.


The control of adrenergic function in heart failure: therapeutic intervention.

Clark A, Cleland J Heart Fail Rev. 2005; 5(1):101-14.

PMID: 16228919 DOI: 10.1023/A:1009854325711.


Agmatine, an endogenous ligand at imidazoline binding sites, does not antagonize the clonidine-mediated blood pressure reaction.

Raasch W, Schafer U, Qadri F, Dominiak P Br J Pharmacol. 2002; 135(3):663-72.

PMID: 11834614 PMC: 1573177. DOI: 10.1038/sj.bjp.0704513.